Celgene Korea urged to further reduce insurance price of Revlimid

Published: 2012-07-20 06:58:00

Updated: 2012-07-20 06:58:00

Celgene is still in a tug of war with the Health Insurance Review and Assessment Service (HIRA) to make its cancer drug Revlimid more affordable to the national health insurance, although the company already reduced the supply price of Revlimid by 52 percent.

In a recent negotiation, the HIRA and Celgene Korea failed to reach an agreement as the former demanded the insurance price of Revlimi...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.